hyper cvad ma


Of the patients, 51 (81%) experienced ≥1 unplanned hospital admission; only 41 (65%) completed six cycles. The cytarabine modifications did not prevent significant toxicity. Modified hyper-CVAD/MA resulted in similar outcomes to CHOP-like chemotherapy in aggressive lymphomas and was associated with significant toxicity.


Hyper‐CVAD was comprised of 300 mg/m 2 of cyclophosphamide administered intravenously (i.v.) over 2–3 hours every 12 hours for 6 doses on Days 1–3, with sodium mercaptoethanesulfonate given at twice the total dose as cyclophosphamide but given by continuous infusion starting with cyclophosphamide and ending 12 hours after the last dose;


Jul 26, 2010 · Toxicity profiles of the chemoimmunotherapy regimens were similar to previous reports detailing modified hyper-CVAD 1 for LL and hyper-CVAD and rituximab for Burkitt-type leukemia/lymphoma. 8,13,17,25 There was no difference in time to CR with the addition of rituximab (median 23 v 21 days).


Between 1994 and 2004, twenty-seven ALL patients received standard induction therapy, and 23 achieved complete remission. Of the 23 patients, 12 were treated with Hyper-CVAD/high dose MTX-Ara-C (H-CVAD/HD-MA) regimen as consolidation therapy; of these patients, 7 (58%) underwent allogeneic stem cell transplantations.


HyperCVAD療法を受けられる患者さまへ No.2 患者氏名: 様 受持医: 受持看護師:

同愛記念病院では、hyper CVAD/MAという治療と、グリベッグという飲み薬による治療をしましたが、寛解にはならずに別の病院へ転院することになりました。


急性リンパ性白血病はJALSGもしくはJSCT研究会の治療プロトコール、もしくはhyper CVAD/MA療法などを行います。 寛解状態(検査で異常を認めない状態)となった患者さんには原則として初回と同様の強力な化学療法である「地固め療法」を数コース行います。

Ph+ALLへの初期治療としてHyper-CVAD+Ponatinib併用療法は有効な可能性、フェーズ2試験より【ASH2013】 2013/12/10 満武里奈=日経メディカル別冊


Modified hyper-CVAD/MA resulted in similar outcomes to CHOP-like chemotherapy in aggressive lymphomas and was associated with significant toxicity. Do you want to read the rest of this article?



Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center We present long‐term survival outcomes from a pivotal phase II trial of rituximab, hyper‐fractionated cyclophosphamide, (R‐HCVAD/MA).


Table IV. Hyper-CVAD alternating with MA Hyper-CVAD (cycles 1, 3, 5, 7) Cyclophosphamide 2300 mg/m IV every 12 hours on days 1-3 (6 doses) with mesna uroprotection Vincristine 2 mg IV on days 4 and 11 Doxorubicin 50 mg/m2 IV over 24 hours on day 4 Dexamethasone 40 mg daily on days 1

Hyper-CVAD as Initial Treatment for ALL. Abstract & Commentary. Synopsis: The chemotherapy regimen Hyper-CVAD is increasingly used for patients with hematological malignancies. In this report from the MD Anderson Cancer Center, clinical outcomes for 288 adults who received first-line treatment with this regimen for acute lymphocytic leukemia were presented.

May 01, 2008 · Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt’s and Burkitt’s -Like Leukemia/Lymphoma. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.


22 ―172― Fig. 3 Clinical course and treatment CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; Hyper-CVAD/MA, hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternat-


R-HyperCVAD R-MA R-HyperCVAD R-MA R-HyperCVAD R-MA R-HyperCVAD R-MA Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered. Day Drug Dose Route Diluent and Rate 1 Methotrexate 12.5mg Intrathecal1 2,3,4,5, 12,13,14,15 Dexamethasone 40mg PO or IV 2 riTUXimab 375mg/m2 IV infusion2 Observe post

CHOP has been the most common regimen used in PbL; however, NCCN guidelines do not consider an adequate therapy, and recommend more intensive regimens such as Hyper-CVAD-MA, CODOX-M/IVAC, or EPOCH (infusional) therapy. 35 About 38% of 5-year progression-free survival (PFS) and a 40% of 5-year OS in patients with PbL, 40% received Hyper-CVAD-MA

The type of salvage regimen affected the PBSC yields in this study, and the EPOCH or bendamustine regimen was associated with good mobilizers. The hyper-CVAD/MA regimen has been reported to be a risk factor for reduced PBSC yields in patients with mantle cell lymphoma, which is consistent with our results . Other factors associated with good



NCCN Guidelines Version 2.2015 AIDS関連B細胞リンパ腫 注意:特に指定のない限り、すべての推奨はカテゴリー2Aである。 臨床試験:NCCNはすべてのがん患者にとって、最良の管理法は臨床試験にあると考えている。臨床試験への参加が特に推奨される。

Patients in Hyper CVAD/MA group are more susceptible to neutropenia (<1.5 × 10⁹/L) (73.9% vs 38.6%, P=0.004). CONCLUSION: The curative effect of Hyper CVAD/MA regimen as induction therapy in treatment of PTCL patients except ALK positive PTCL patients

化学療法としては高強度の治療が行われることが多く、当院では治療に耐えられる方であればR-hyper CVAD/MA交代療法を行っています。 末梢性T細胞リンパ腫


Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013. Brenner DJ, Hall EJ.

Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic


Notably, when using DA–EPOCH‐R, complete blood counts should be checked twice weekly as the nadirs of neutrophils and platelets guide the dose adjustment for the following cycle, which is an intrinsic component of this regimen. Younger patients can also be considered for R–CODOX‐M/R‐IVAC or R–hyper‐CVAD/MA.

Oct 29, 2019 · 進行が早く再発率も高いことが予想されたため、悪性リンパ腫では一般的な標準治療でもある【R-CHOP療法】より強力な【R/Hyper CVAD/R-MA療法】を


7 化学療法と帯状疱疹の発症頻度に 関連はあるのか? 悪性リンパ腫症例における 帯状疱疹合併例の検討 悪性リンパ 腫の治療はリツキシマブの 導入により 向上して

The authors of this long-term follow-up of a prospective, multi-institution, phase II trial evaluated the safety and efficacy of rituximab plus hyper-CVAD alternating with methotrexate (MTX)/cytarabine (R-HCVAD/MA) as first-line therapy in 97 patients with mantle cell lymphoma (MCL).

Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology. 2005 Dec 1;23(28):7013-7023.


The initial study design was based on our previous experience with hyper-CVAD plus imatinib or dasatinib, for which the reported median event-free survival was 24 months. The current study has 94% power to prove if the combination of hyper-CVAD and ponatinib can achieve an improvement in median event-free survival to 36 months.


In patients with newly diagnosed MCL, R-HCVAD/MA showed sustained efficacy, with a median OS exceeding 10 years in all patients and freedom from disease recurrence of nearly 15 years in almost one-third of the younger patients (≤65 years). KW – Hyper-CVAD. KW – Mantle cell lymphoma. KW – Methotrexate. KW – Secondary malignancy. KW – Treatment

Nursing. Forthcoming section for nursing specific resources on caring for patients with lymphomas.


Initial therapy with 4 cycles of denileukin diftitox resulted in restoration of normal hematopoiesis and a reduction in bone marrow myelofibrosis. After disease progression, 4 cycles of hyper-CVAD were administered and a complete clinical remission was achieved.

After six cycles of hyper-CVAD/MA regimen, PET-CT showed no uptake of FDG, suggesting complete remission (CR). Then, he underwent autologous hematopoietic stem cell transplantation (AHSCT) as


*See NCCP Regimen 00466 rituximab Hyper-CVAD Therapy (MCL)-Part A for details. Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 R-HyperCVAD R-MA R-HyperCVAD R-MA R-HyperCVAD R-MA R-HyperCVAD R-MA Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.


Building on the success of the hyper-CVAD regimen, successive studies from the MDACC group incorporated TKIs into this backbone, beginning with the first-generation TKI imatinib and followed by the second- and third-generation TKIs dasatinib and ponatinib, respectively, to explore their efficacy in


(Hyper- CVAD/MA) in Patients ≥ 60 _____ Give Leucovorin 15mg+50mL D5W IVPB over 15 minutes Q6 hours for 8 doses starting 24 hours after the completion of MTX Increase Leucovorin to 50mg+50mL D5W IVPB over 15 minutes Q6 hours if any of the MTX levels are elevated as below and


CVAD療法と同時に開始された.なお, R-hyper CVAD 療 法を施行する際の抗癌薬の投与量は体表面積1.4で算定し, MA療法を施行する際は体重減少により体表面積1.34で算 定した. 化学療法のプロトコールは, R-hyper CVAD 療法が1コ

『 Hyper-CVAD / MA療法 ② 』 の2つが考えられるそうです。 寛解率でみると、 『JALSG ALL97』74%に対して 『Hyper-CVAD / MA療法』92%であることから、 後者の療法を行うことになりました。 まず1クール目に ”表”と言われる『Hyper-CVAD』を行い、 2クール目に

Hyper-CVAD is one of the most widely used regimens in adults with ALL, especially outside of the academic setting. Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014;32

Blinatumomab is a CD19/CD3 bispescific antibody designed to redirect T cells toward malignant B cells and induce their lysis. It recently gained accelerated approval by the FDA for the treatment of relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (RR-ALL). In the phase II trial that served as the basis for approval, blinatumomab demonstrated

Sep 04, 2014 · 悪性リンパ腫(仙骨部)のMRI画像。抗がん剤治療Hyper-CVAD/MA療法の2コース目終了後。 関連ブログ. 抗がん剤で縮小した悪性

閲覧数: 742

[Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old]. Huang AJ, Wang LB, Du J, Tang GS, Cheng H, Gong SL, Gao L, Qiu HY, Ni X, Chen J, Chen L, Zhang WP, Wang JM, Yang JM, Hu XX


High Ki-67 is strongly associated with the risk of CNS relapse in patients with mantle cell lymphoma. Two-year incidence of CNS relapse in patients with Ki-67 ≥ 30 exceeds 25%. The incidence was not decreased by rituximab, high-dose cytarabine, high-dose methotrexate or consolidative ASCT. Development of new prophylactic strategies for CNS involvement is mandatory in patients with high Ki

Hyper-CVAD – Wiley Online Library Oct 12, 2004 – ously accepted categories, as well as visualization of the Martingale . were divided into good-risk (risk score 0â 1; 37%), in- termediate risk

Back to top